Immutep Reveals Promising Data for IMP761 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2024
0mins
Should l Buy ?
Source: Business Insider
Immutep Ltd Update: Immutep Limited has reported initial safety data from its Phase I trial of IMP761, a LAG-3 agonist antibody, with no adverse events noted, indicating potential for treating autoimmune diseases.
Investor Interest: The positive trial results have attracted investor attention, with further data anticipated in 2025 as the study progresses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
